Patients who had no anti-tumor response to high-dose IL-2 had significantly greater expansion of Treg cells compared to patients with objective anti-tumor responses, suggesting an association of the inhibitory role of these cells with poor clinical response (Figure 1A) [20,21,22]. The gene discussed is IL2; the disease is neoplasm.